The Silicon Review - Best Business Review Magazine 50 Most Trustworthy Companies 2019 | Page 114

Abbvie’s Relentless Drive to Discover Promising New Immunology
Pathways is Inspired and Guided by Those Whose Lives are Touched
by Immune-Mediated Diseases
“We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science.”
T
he global pharmaceuticals
industry is integral to modern
medicine and healthcare.
From conducting research on
various life-threatening diseases to
compiling data about public health,
pharmaceuticals make up an industry
that is valued at a few hundred billion
dollars. Numerous pharmaceutical
corporations pour hundreds of
millions of dollars in research each
year.
Abbvie is one of the world’s
leading pharmaceutical research
organizations. Its employees
consist of about 30,000 employees
are scientists, researchers,
communicators, manufacturing
specialists and regulatory experts
located around the globe. Abbvie
comes up with new approaches to
addressing today’s health issues—
from life-threatening illness to
chronic conditions. The company
targets specific difficult-to-cure
diseases where it can leverage its
core R&D expertise to advance
science. The team at Abbvie is
constantly working to create
solutions that go beyond treating the
illness to have a positive impact on
patients’ lives, on societies—and on
science itself.
114
Abbvie is driven by a compassion for
people, commitment to innovation
and inclusion, service to the
community, and uncompromising
integrity at the heart of everything it
does.
Here are Abbvie’s areas
of expertise:
Immunology
The company’s relentless drive to
discover promising new immunology
pathways and targets is inspired
and guided by those whose lives
are touched by immune-mediated
diseases. Its current successes
motivate us to continue that
exploration, strengthening its resolve
as it strives to impact their disease
and their evolving expectations for a
life better-lived.
AbbVie has 8,000+ research and
development team members at the
forefront of discovering, developing
and delivering therapies to solve
unmet patient needs. The company’s
innovation and expertise are
powered by leading scientists, whose
work continues to pave the way for
new generations of researchers – and
we all share the goal of identifying
therapeutic approaches that have
remarkable impacts for patients
everywhere.
Antibody Drug
Conjugates (ADCs)
This technology platform uses the
targeting of an antibody to deliver a
therapeutic agent. ADC technology
is more traditionally used in
Oncology; however, by coupling a
highly potent immunomodulator to
an anti-inflammatory monoclonal
antibody, it can be delivered to
dysregulated immune cells with the
goal to turn down inflammation,
restore normal immune function and
spare normal tissue. By combining
AbbVie’s expertise in discovering
and developing specific monoclonal
antibodies with its experience in
small molecule chemistry – AbbVie
is leading the field in applying ADC
technology to immune-mediated
diseases.
Oncology
AbbVie scientists combine deep
biologic knowledge with cutting-
edge research technology to advance
cancer care.
Immuno-Oncology
•
•
•
•
•
Relies on the immune
response and the immunologic
memory
The immunologic memory is
a distinct characteristic of the
immune system. It allows our
immune systems to quickly and
specifically recognize an antigen
that our bodies have previously
encountered
There are two types of immune
responses, the innate and the
adaptive
The innate response is an
antigen-independent response
that is immediate and has no
immunologic memory
The adaptive response is
an antigen-dependent and
antigen-specific response with
the capacity for immunologic
memory